Disorders & Diseases of the Basal Ganglia (incl. Stroke)

Movement Disorders Following Cerebrovascular Lesion in the Basal Ganglia Circuit

Disorders & Diseases of the Basal Ganglia (incl. Stroke)

1. Ghika-Schmid F, Ghika J, Regli F, Bogousslavsky J. Hyperkinetic movement disorders during and after acute stroke: the Lausanne Stroke Registry. J Neurol Sci. 1997;146:109–116. [PubMed] [Google Scholar]

2. Siniscalchi A, Gallelli L, Labate A, Malferrari G, Palleria C, Sarro GD. Post-stroke movement disorders: clinical manifestations and pharmacological management. Curr Neuropharmacol. 2012;10:254–262. [PMC free article] [PubMed] [Google Scholar]

3. Alarcón F, Zijlmans JC, Dueñas G, Cevallos N. Post-stroke movement disorders: report of 56 patients. J Neurol Neurosurg Psychiatry. 2004;75:1568–1574. [PMC free article] [PubMed] [Google Scholar]

4. Wolters EC, Van Laar T, Berendse HW. Parkinsonism and related disorders. 3rd ed. Amsterdam: VU University Press; 2010. [Google Scholar]

5. Fahn S, Jankovic J, Hallett M. Principles and practice of movement disorders. Philadelphia: Elsevier Health Sciences; 2011. [Google Scholar]

6. Nougaret S, Meffre J, Duclos Y, Breysse E, Pelloux Y. First evidence of a hyperdirect prefrontal pathway in the primate: precise organization for new insights on subthalamic nucleus functions. Front Comput Neurosci. 2013;7:135. [PMC free article] [PubMed] [Google Scholar]

7. Nambu A, Tokuno H, Takada M. Functional significance of the cortico-subthalamo-pallidal ‘hyperdirect’ pathway. Neurosci Res. 2002;43:111–117. [PubMed] [Google Scholar]

8. Handley A, Medcalf P, Hellier K, Dutta D. Movement disorders after stroke. Age Ageing. 2009;38:260–266. [PubMed] [Google Scholar]

9. Mehanna R, Jankovic J. Movement disorders in cerebrovascular disease. Lancet Neurol. 2013;12:597–608. [PubMed] [Google Scholar]

10. Scott BL, Jankovic J. Delayed-onset progressive movement disorders after static brain lesions. Neurology. 1996;46:68–74. [PubMed] [Google Scholar]

11. Zijlmans JC, Daniel SE, Hughes AJ, Révész T, Lees AJ. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord. 2004;19:630–640. [PubMed] [Google Scholar]

12. Lin B, Levy S, Raval AP, Perez-Pinzon MA, Defazio RA. Forebrain ischemia triggers GABAergic system degeneration in substantia nigra at chronic stages in rats. Cardiovasc Psychiatry Neurol. 2010;2010:506952. [PMC free article] [PubMed] [Google Scholar]

13. Nagasawa H, Araki T, Kogure K. Alteration of dopamine D1 receptor in the strionigral system of the postischemic rat brain. Neurosci Lett. 1992;134:271–274. [PubMed] [Google Scholar]

14. Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain. 1994;117(Pt 4):859–876. [PubMed] [Google Scholar]

15. Holtbernd F, Eidelberg D. Functional brain networks in movement disorders: recent advances. Curr Opin Neurol. 2012;25:392–401. [PMC free article] [PubMed] [Google Scholar]

16. Ohye C, Le Gayader C, Feger J. Responses of subthalamic and pallidal neurons to striatal stimulation: an extracellular study on awake monkeys. Brain Res. 1976;111:241–252. [PubMed] [Google Scholar]

17. Vannucci RC. Mechanisms of perinatal hypoxic-ischemic brain damage. Semin Perinatol. 1993;17:330–337. [PubMed] [Google Scholar]

18. Chung SJ, Im JH, Lee MC, Kim JS. Hemichorea after stroke: clinical-radiological correlation. J Neurol. 2004;251:725–729. [PubMed] [Google Scholar]

19. Crossman AR, Sambrook MA, Jackson A. Experimental hemichorea/hemiballismus in the monkey. Studies on the intracerebral site of action in a drug-induced dyskinesia. Brain. 1984;107(Pt 2):579–596. [PubMed] [Google Scholar]

20. Albin RL. The pathophysiology of chorea/ballism and Parkinsonism. Parkinsonism Relat Disord. 1995;1:3–11. [PubMed] [Google Scholar]

21. Bhidayasiri R, Truong DD. Chorea and related disorders. Postgrad Med J. 2004;80:527–534. [PMC free article] [PubMed] [Google Scholar]

22. Vidaković A, Dragasević N, Kostić VS. Hemiballism: report of 25 cases. J Neurol Neurosurg Psychiatry. 1994;57:945–949. [PMC free article] [PubMed] [Google Scholar]

23. Bansil S, Prakash N, Kaye J, Wrigley S, Manata C, Stevens-Haas C, et al. Movement disorders after stroke in adults: a review. Tremor Other Hyperkinet Mov (N Y) 2012 Mar 20; [Epub]. http://dx.doi.org/10.7916/D86W98TB. [PMC free article] [PubMed] [Google Scholar]

24. Whittier JR. Ballism and the subthalamic nucleus hypothalamicus; corpus luysi) review of the literature and study of 30 cases. Arch Neurol Psychiatry. 1947;58:672–692. [PubMed] [Google Scholar]

25. Krauss JK, Pohle T, Borremans JJ. Hemichorea and hemiballism associated with contralateral hemiparesis and ipsilateral basal ganglia lesions. Mov Disord. 1999;14:497–501. [PubMed] [Google Scholar]

26. Takahashi T, Kanamori H, Shigehara R, Takahashi SN, Tamura M, Takasu T, et al. Pure hemi-chorea resulting from an acute phase of contralateral thalamic lacunar infarction: a case report. Case Rep Neurol. 2012;4:194–201. [PMC free article] [PubMed] [Google Scholar]

27. Vidailhet M, Grabli D, Roze E. Pathophysiology of dystonia. Curr Opin Neurol. 2009;22:406–413. [PubMed] [Google Scholar]

28. Fross RD, Martin WR, Li D, Stoessl AJ, Adam MJ, Ruth TJ, et al. Lesions of the putamen: their relevance to dystonia. Neurology. 1987;37:1125–1129. [PubMed] [Google Scholar]

29. Netravathi M, Pal PK, Indira Devi B. A clinical profile of 103 patients with secondary movement disorders: correlation of etiology with phenomenology. Eur J Neurol. 2012;19:226–233. [PubMed] [Google Scholar]

30. Pettigrew LC, Jankovic J. Hemidystonia: a report of 22 patients and a review of the literature. J Neurol Neurosurg Psychiatry. 1985;48:650–657. [PMC free article] [PubMed] [Google Scholar]

31. Chuang C, Fahn S, Frucht SJ. The natural history and treatment of acquired hemidystonia: report of 33 cases and review of the literature. J Neurol Neurosurg Psychiatry. 2002;72:59–67. [PMC free article] [PubMed] [Google Scholar]

32. Lee MS, Marsden CD. Movement disorders following lesions of the thalamus or subthalamic region. Mov Disord. 1994;9:493–507. [PubMed] [Google Scholar]

33. Baik JS, Lee MS. Movement disorders associated with moyamoya disease: a report of 4 new cases and a review of literatures. Mov Disord. 2010;25:1482–1486. [PubMed] [Google Scholar]

34. Kim JS. Delayed onset mixed involuntary movements after thalamic stroke: clinical, radiological and pathophysiological findings. Brain. 2001;124(Pt 2):299–309. [PubMed] [Google Scholar]

35. Krystkowiak P, Martinat P, Defebvre L, Pruvo JP, Leys D, Destée A. Dystonia after striatopallidal and thalamic stroke: clinicoradiological correlations and pathophysiological mechanisms. J Neurol Neurosurg Psychiatry. 1998;65:703–708. [PMC free article] [PubMed] [Google Scholar]

36. Kojovic M, Cordivari C, Bhatia K. Myoclonic disorders: a practical approach for diagnosis and treatment. Ther Adv Neurol Disord. 2011;4:47–62. [PMC free article] [PubMed] [Google Scholar]

37. Espay AJ, Chen R. Myoclonus. Continuum (Minneap Minn) 2013;19(5 Movement Disorders):1264–1286. [PubMed] [Google Scholar]

38. Defebvre L. Myoclonus and extrapyramidal diseases. Neurophysiol Clin. 2006;36:319–325. [PubMed] [Google Scholar]

39. Bogousslavsky J, Caplan LR. Stroke syndromes. 2nd ed. Cambridge: Cambridge University Press; 2001. [Google Scholar]

40. Kim JS. Asterixis after unilateral stroke: lesion location of 30 patients. Neurology. 2001;56:533–536. [PubMed] [Google Scholar]

41. Massey EW, Goodman JC, Stewart C, Brannon WL. Unilateral asterixis: motor integrative dysfunction in focal vascular disease. Neurology. 1979;29:1180–1182. [PubMed] [Google Scholar]

42. Miwa H, Hatori K, Kondo T, Imai H, Mizuno Y. Thalamic tremor: case reports and implications of the tremor-generating mechanism. Neurology. 1996;46:75–79. [PubMed] [Google Scholar]

43. Nowak DA, Seidel B, Reiner B. Tremor following ischemic stroke of the posterior thalamus. J Neurol. 2010;257:1934–1936. [PubMed] [Google Scholar]

44. Cho C, Samkoff LM. A lesion of the anterior thalamus producing dystonic tremor of the hand. Arch Neurol. 2000;57:1353–1355. [PubMed] [Google Scholar]

45. Krystkowiak P, Martinat P, Cassim F, Pruvo JP, Leys D, Guieu JD, et al. Thalamic tremor: correlations with three-dimensional magnetic resonance imaging data and pathophysiological mechanisms. Mov Disord. 2000;15:911–918. [PubMed] [Google Scholar]

46. Kim JS. Delayed onset hand tremor caused by cerebral infarction. Stroke. 1992;23:292–294. [PubMed] [Google Scholar]

47. Lehéricy S, Vidailhet M, Dormont D, Piérot L, Chiras J, Mazetti P, et al. Striatopallidal and thalamic dystonia. A magnetic resonance imaging anatomoclinical study. Arch Neurol. 1996;53:241–250. [PubMed] [Google Scholar]

48. Kwak CH, Jankovic J. Tourettism and dystonia after subcortical stroke. Mov Disord. 2002;17:821–825. [PubMed] [Google Scholar]

49. Gomis M, Puente V, Pont-Sunyer C, Oliveras C, Roquer J. Adult onset simple phonic tic after caudate stroke. Mov Disord. 2008;23:765–766. [PubMed] [Google Scholar]

50. Peterson BS. Neuroimaging studies of Tourette syndrome: a decade of progress. Adv Neurol. 2001;85:179–196. [PubMed] [Google Scholar]

51. Keane JR, Young JA. Blepharospasm with bilateral basal ganglia infarction. Arch Neurol. 1985;42:1206–1208. [PubMed] [Google Scholar]

52. Grandas F, López-Manzanares L, Traba A. Transient blepharospasm secondary to unilateral striatal infarction. Mov Disord. 2004;19:1100–1102. [PubMed] [Google Scholar]

53. Schmidt KE, Linden DE, Goebel R, Zanella FE, Lanfermann H, Zubcov AA. Striatal activation during blepharospasm revealed by fMRI. Neurology. 2003;60:1738–1743. [PubMed] [Google Scholar]

54. Sechi G, Agnetti V, Galistu P, Murgia B, Marrosu F, Puligheddu M, et al. Restless legs syndrome and periodic limb movements after ischemic stroke in the right lenticulostriate region. Parkinsonism Relat Disord. 2008;14:157–160. [PubMed] [Google Scholar]

55. Lee SJ, Kim JS, Song IU, An JY, Kim YI, Lee KS. Poststroke restless legs syndrome and lesion location: anatomical considerations. Mov Disord. 2009;24:77–84. [PubMed] [Google Scholar]

56. Wetter TC, Eisensehr I, Trenkwalder C. Functional neuroimaging studies in restless legs syndrome. Sleep Med. 2004;5:401–406. [PubMed] [Google Scholar]

57. Peters S, Eising EG, Przuntek H, Müller T. Vascular parkinsonism: a case report and review of the literature. J Clin Neurosci. 2001;8:268–271. [PubMed] [Google Scholar]

58. Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol. 1999;56:98–102. [PubMed] [Google Scholar]

59. Gupta D, Kuruvilla A. Vascular parkinsonism: what makes it different? Postgrad Med J. 2011;87:829–836. [PubMed] [Google Scholar]

60. Zijlmans JC, Thijssen HO, Vogels OJ, Kremer HP, Poels PJ, Schoonderwaldt HC, et al. MRI in patients with suspected vascular parkinsonism. Neurology. 1995;45:2183–2188. [PubMed] [Google Scholar]

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886205/

Parkinson Disease: Practice Essentials, Background, Anatomy

Disorders & Diseases of the Basal Ganglia (incl. Stroke)

  1. Hauser RA, Grosset DG. [(123) I]FP-CIT (DaTscan) SPECT Brain Imaging in Patients with Suspected Parkinsonian Syndromes. J Neuroimaging. 2011 Mar 16. [Medline].

  2. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011 Jun. 26 Suppl 1:S1-58. [Medline].

  3. Anderson P. More Evidence Links Pesticides, Solvents, With Parkinson's. Medscape Medical News. Available at http://www.medscape.com/viewarticle/804834. Accessed: June 11, 2013.

  4. Pezzoli G, Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology. 2013 May 28. 80(22):2035-41. [Medline].

  5. Liu R, Guo X, Park Y, Huang X, Sinha R, Freedman ND, et al. Caffeine Intake, Smoking, and Risk of Parkinson Disease in Men and Women. Am J Epidemiol. 2012 Apr 13. [Medline].

  6. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology. 1985 Jul. 35(7):949-56. [Medline].

  7. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, et al. Parkinson disease in twins: an etiologic study. JAMA. 1999 Jan 27. 281(4):341-6. [Medline].

  8. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997 Jun 27. 276(5321):2045-7. [Medline].

  9. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998 Feb. 18(2):106-8. [Medline].

  10. Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol. 2010 Dec. 23(4):228-42. [Medline]. [Full Text].

  11. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Ross BM, et al. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol. 2010 Sep. 67(9):1116-22. [Medline].

  12. Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother. 2007 Apr. 8(5):657-64. [Medline].

  13. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of a-synuclein in neurological disorders. Lancet Neurol. 2011 Nov. 10(11):1015-25. [Medline].

  14. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body- pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008 May. 14(5):504-6. [Medline].

  15. Dalvin LA, Damento GM, Yawn BP, Abbott BA, Hodge DO, Pulido JS. Parkinson Disease and Melanoma: Confirming and Reexamining an Association. Mayo Clin Proc. 2017 Jul. 92 (7):1070-1079. [Medline].

  16. Mulcahy, N. Melanoma, Parkinson's: See One, Be Aware of the Other. Medscape Medical News. Available at http://www.medscape.com/viewarticle/883195. July 19, 2017; Accessed: July 26, 2017.

  17. Constantinescu R, Elm J, Auinger P, Sharma S, Augustine EF, Khadim L, et al. Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial. Mov Disord. 2014 Feb. 29 (2):263-5. [Medline].

  18. De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT. Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology. 2018 Jun 13. [Medline].

  19. Muangpaisan W, Mathews A, Hori H, Seidel D. A systematic review of the worldwide prevalence and incidence of Parkinson's disease. J Med Assoc Thai. 2011 Jun. 94(6):749-55. [Medline].

  20. Grimes DA, Lang AE. Treatment of early Parkinsons disease. Can J Neurol Sci. 1999 Aug. 26 Suppl 2:S39-44. [Medline].

  21. Thobois S, Delamarre-Damier F, Derkinderen P. Treatment of motor dysfunction in Parkinsons disease: an overview. Clin Neurol Neurosurg. 2005 Jun. 107(4):269-81. [Medline].

  22. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr 11. 66(7):968-75. [Medline].

  23. National Collaborating Centre for Chronic Conditions. Parkinson's disease: National clinical guideline for diagnosis and management in primary and secondary care. London, UK: Royal College of Physicians; 2006.

  24. Hughes S. Consider Nonmotor Symptoms for Diagnosis of Parkinson's? Medscape Medical News. January 18, 2013. Available at http://www.medscape.com/viewarticle/777874. Accessed: January 22, 2013.

  25. Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O'Brien JT, Brooks DJ, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013 Jan 15. 80(3):276-81. [Medline].

  26. Simuni T, Sethi K. Nonmotor manifestations of Parkinson's disease. Ann Neurol. 2008 Dec. 64 Suppl 2:S65-80. [Medline].

  27. Sato Y, Iwamoto J, Honda Y. Vitamin D Deficiency-Induced Vertebral Fractures May Cause Stooped Posture in Parkinson Disease. Am J Phys Med Rehabil. 2011 Jan 5. [Medline].

  28. Brin MF, Velickovic M, Remig LO. Dysphonia due to Parkinson's disease; pharmacological, surgical, and behavioral management perspectives. Vocal Rehabilitation in Medical Speech-Language Pathology. Austin: Pro-Ed; 2004. 209-69.

  29. Perez KS, Ramig LO, Smith ME, Dromey C. The Parkinson larynx: tremor and videostroboscopic findings. J Voice. 1996 Dec. 10(4):354-61. [Medline].

  30. Ray Chaudhuri K, Rojo JM, Schapira AH, Brooks DJ, Stocchi F, Odin P, et al. A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One. 2013. 8(2):e57221. [Medline]. [Full Text].

  31. Johnson K. Nonmotor PD Symptoms Bolster Disease Severity Assessment. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/812182. Accessed: October 13, 2013.

  32. Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009 Nov 24. 73(21):1738-45. [Medline]. [Full Text].

  33. Weintraub D, Comella CL, Horn S. Parkinson's disease–Part 3: Neuropsychiatric symptoms. Am J Manag Care. 2008 Mar. 14(2 Suppl):S59-69. [Medline].

  34. Reid WG, Hely MA, Morris JG, Loy C, Halliday GM. Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry. 2011 Sep. 82(9):1033-7. [Medline].

  35. Parkinson's Tied to Higher Risk of Osteoporosis and Osteopenia. Medscape. Apr 3 2014. [Full Text].

  36. Torsney KM, Noyce AJ, Doherty KM, et al. Bone health in Parkinson's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2014 Mar 21. [Medline].

  37. Tolosa E, Gaig C, Santamaría J, Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology. 2009 Feb 17. 72(7 Suppl):S12-20. [Medline].

  38. Fluorodopa F18 (fluorodeoxyphenylalanine 18F-DOPA) [package insert]. Manhasset, NY: Feinstein Institutes for Medical Research; Cyclotron/Radiochemistry Facility. October 2019. Available at [Full Text].

  39. King J. New contrast agent enables earlier diagnosis in Parkinson's. Medscape Medical News. June 18, 2013. [Full Text].

  40. Seibyl J, Jennings D, Grachev I, Coffey C, Marek K. Accuracy of DaTscan™ (ioflupane I 123 injection) in diagnosis of early parkinsonian syndromes (PS) [abstract 191]. Presented at: 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI); June 10, 2013; Vancouver, British Columbia, Canada.

  41. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004 Oct. 318(1):121-34. [Medline].

  42. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, et al. Association of Cerebrospinal Fluid ß-Amyloid 1-42, T-tau, P-tau181, and a-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. JAMA Neurol. 2013 Aug 26. [Medline].

  43. Jeffrey S. Biomarkers for Parkinson's Diagnostic, Prognostic. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/810262. Accessed: September 9, 2013.

  44. Grosset D, Taurah L, Burn DJ, MacMahon D, Forbes A, Turner K, et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry. 2007 May. 78(5):465-9. [Medline]. [Full Text].

  45. Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Cochrane Database Syst Rev. 2009. (4):CD006661. [Medline].

  46. Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. Drug Saf. 2009. 32(6):475-88. [Medline].

  47. Bayulkem K, Lopez G. Clinical approach to nonmotor sensory fluctuations in Parkinson's disease. J Neurol Sci. 2011 Nov 15. 310(1-2):82-5. [Medline].

  48. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr 11. 66(7):996-1002. [Medline].

Source: https://emedicine.medscape.com/article/1831191-overview